O., Giri, N., McReynolds, L
In the larger SELECT trial in 2023, patients with heart failure, atherosclerotic disease, and overweight or obesity, treated with semaglutide 2.4 mg showed reduction in major adverse cardiac events (MACE) and heart failure end points regardless of heart failure subgroup being HFrEF or HFpEF [56,57,58]
Patients presenting with severe, persistent abdominal pain radiating to the back, accompanied by nausea and vomiting, require urgent assessment
It takes just minutes to make but the benefits last so much longer